These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 28301793)
1. Advances in rheumatoid arthritis. Jones G; Nash P; Hall S Med J Aust; 2017 Mar; 206(5):221-224. PubMed ID: 28301793 [TBL] [Abstract][Full Text] [Related]
2. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars. Woodworth TG; den Broeder AA Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765 [TBL] [Abstract][Full Text] [Related]
3. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Braun J; Kay J Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848 [TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab. Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924 [TBL] [Abstract][Full Text] [Related]
5. Anti-TNF treatment in rheumatoid arthritis. Geiler J; Buch M; McDermott MF Curr Pharm Des; 2011; 17(29):3141-54. PubMed ID: 21864263 [TBL] [Abstract][Full Text] [Related]
6. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. Zhao S; Chadwick L; Mysler E; Moots RJ Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512 [TBL] [Abstract][Full Text] [Related]
8. Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. Hopkins AM; Proudman SM; Vitry AI; Sorich MJ; Cleland LG; Wiese MD Med J Aust; 2016 Feb; 204(2):64-8. PubMed ID: 26821102 [TBL] [Abstract][Full Text] [Related]
9. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis. Yoo DH Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131 [TBL] [Abstract][Full Text] [Related]
11. Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis. Osiri M; Dilokthornsakul P; Chokboonpium S; Suthipinijtham P; Koolvisoot A Adv Ther; 2021 Sep; 38(9):4885-4899. PubMed ID: 34370276 [TBL] [Abstract][Full Text] [Related]
12. Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. Bonek K; Roszkowski L; Massalska M; Maslinski W; Ciechomska M Cells; 2021 Feb; 10(2):. PubMed ID: 33557301 [TBL] [Abstract][Full Text] [Related]
13. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies. Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905 [TBL] [Abstract][Full Text] [Related]
14. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis. Mengato D; Messori A Clin Exp Rheumatol; 2018; 36(6):1118. PubMed ID: 29600941 [No Abstract] [Full Text] [Related]
15. Etanercept for the treatment of rheumatoid arthritis. Zhao S; Mysler E; Moots RJ Immunotherapy; 2018 Mar; 10(6):433-445. PubMed ID: 29482402 [TBL] [Abstract][Full Text] [Related]
16. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. Aladul MI; Fitzpatrick RW; Chapman SR BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626 [TBL] [Abstract][Full Text] [Related]
18. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. Smolen JS; Caporali R; Doerner T; Fautrel B; Benedetti F; Pieper B; Jang M RMD Open; 2021 Jun; 7(2):. PubMed ID: 34099538 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. Lu X; Hu R; Peng L; Liu M; Sun Z Front Immunol; 2021; 12():638444. PubMed ID: 33889152 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]